Q2 EPS Forecast for Alto Neuroscience Lowered by Analyst

Alto Neuroscience, Inc. (NYSE:ANRO) – Equities researchers at HC Wainwright reduced their Q2 2026 EPS estimates for shares of Alto Neuroscience in a research report issued on Wednesday, May 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.75) for the quarter, down from their prior forecast of ($0.67). HC Wainwright currently has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.98) per share. HC Wainwright also issued estimates for Alto Neuroscience’s Q3 2026 earnings at ($0.72) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($2.98) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.09) EPS, Q3 2027 earnings at ($1.15) EPS, Q4 2027 earnings at ($1.11) EPS, FY2027 earnings at ($4.39) EPS, FY2028 earnings at ($4.81) EPS, FY2029 earnings at ($3.50) EPS and FY2030 earnings at ($1.53) EPS.

A number of other research analysts also recently commented on ANRO. JonesTrading lowered their price target on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday, April 2nd. BTIG Research upped their price target on shares of Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. Bank of America started coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They set a “buy” rating and a $35.00 price target on the stock. Jefferies Financial Group reiterated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a report on Monday, March 16th. Finally, Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a report on Sunday, May 17th. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $35.25.

Alto Neuroscience Stock Down 1.0%

Shares of NYSE:ANRO opened at $20.24 on Friday. The company has a current ratio of 20.52, a quick ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience has a 12 month low of $2.15 and a 12 month high of $28.44. The company has a 50-day moving average price of $23.04 and a 200 day moving average price of $19.07. The company has a market cap of $710.22 million, a price-to-earnings ratio of -8.36 and a beta of 1.62.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24).

Hedge Funds Weigh In On Alto Neuroscience

Several hedge funds have recently added to or reduced their stakes in ANRO. Invesco Ltd. bought a new position in Alto Neuroscience during the 1st quarter valued at about $67,000. AQR Capital Management LLC bought a new position in Alto Neuroscience during the 1st quarter valued at about $52,000. Marshall Wace LLP grew its holdings in Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock valued at $2,062,000 after purchasing an additional 84,417 shares during the last quarter. Jane Street Group LLC bought a new position in Alto Neuroscience during the 2nd quarter valued at about $240,000. Finally, Bridgeway Capital Management LLC grew its holdings in Alto Neuroscience by 85.9% during the 2nd quarter. Bridgeway Capital Management LLC now owns 54,100 shares of the company’s stock valued at $119,000 after purchasing an additional 25,000 shares during the last quarter.

Key Headlines Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $50 price target on Alto Neuroscience, signaling continued upside confidence despite the earnings cuts.
• Positive Sentiment: Alto added Andrew Miller, Ph.D. to its Board of Directors, a move that may be viewed as strengthening governance and strategic expertise. Article Title
• Neutral Sentiment: The company expanded its board, which is a routine governance update, but could support investor confidence over time. Article Title
• Negative Sentiment: HC Wainwright lowered its EPS estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, FY2026, FY2027, FY2028, FY2029, and FY2030, reinforcing the view that losses may persist longer than previously expected.
• Negative Sentiment: The steepest revisions were to longer-term earnings, including FY2027 and FY2028, which can weigh on sentiment if investors were expecting a faster path to profitability.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.